18 Analysts Have This To Say About Crinetics Pharmaceuticals
18 Analysts Have This To Say About Crinetics Pharmaceuticals
18 位分析師對Crinetics Pharmicals有這樣的看法
In the last three months, 18 analysts have published ratings on Crinetics Pharmaceuticals (NASDAQ:CRNX), offering a diverse range of perspectives from bullish to bearish.
在過去的三個月中，18位分析師公佈了對Crinetics Pharmicals（納斯達克股票代碼：CRNX）的評級，提供了從看漲到看跌的不同視角。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表簡要概述了分析師最近的評級，提供了對過去30天情緒變化的見解，並與前幾個月進行了比較以獲得整體視角。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $62.78, a high estimate of $97.00, and a low estimate of $48.00. This upward trend is apparent, with the current average reflecting a 24.89% increase from the previous average price target of $50.27.
分析師分析的12個月目標股價提供了見解，平均目標股價爲62.78美元，最高估計爲97.00美元，低估值爲48.00美元。這種上升趨勢顯而易見，當前的平均價格較之前的50.27美元的平均目標股價上漲了24.89％。
Breaking...
分...
登入免費觀看全文
登入/註冊